Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity

Hormone and Metabolic Research

Volumn 40, Issue 10, 2008, Pages 702-707

  Anastasilakis, A D ^a,c   Efstathiadou, Z ^a   Plevraki, E ^a   Koukoulis, G N ^b   Slavakis, A ^a   Kita, M ^a   Avramidis, A ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c NONE   (Greece)

Author keywords

Glucose homeostasis; Insulin sensitivity; Parathyroid hormone; Primary hyperparathyroidism; Teriparatide

Indexed keywords

GLUCOSE; INSULIN; PARATHYROID HORMONE; RECOMBINANT PARATHYROID HORMONE; RECOMBINANT PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN SENSITIVITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DEMOGRAPHY; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; RECOMBINANT PROTEINS; TERIPARATIDE;

EID: 54049099231     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1078729     Document Type: Article

References (35)

1. Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 1985; 60: 229-233
2. Saxe AW, Gibson G, Gingerich RL, Levy J. Parathyroid hormone decreases in vivo insulin effect on glucose utilization. Calcif Tissue Int 1995; 57: 127-132
3. Richards ML, Thompson NW. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy? Surgery 1999; 126: 1160-1166
4. Chiu KC, Chuang LM, Lee NP et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000; 49: 1501-1505
5. Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001; 17: 175-180
6. Procopio M, Magro G, Cesario F et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19: 958-961
7. Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest 2003; 26: 1136-1142
8. Khaleeli A, Johnson J, Taylor W. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev 2007; 23: 43-48
9. Wareham N, Byrne C, Carr C et al. Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 1997; 46: 1171-1177
10. Wermers R, Khosla S, Atkinson E et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med 1997; 126: 433-440
11. MacCallum R, Parameswaran V, Burgess J. Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. Clin Endocrinol (Oxf) 2006; 65: 163-168
12. Fallo F, Cella G, Casonato A et al. Biochemical markers of endothelial activation in primary hyperparathyroidism. Horm Metab Res 2006; 38: 125-129
13. Valdemarsson S, Lindblom P, Bergenfelz A. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med 1998; 244: 241-249
14. Kovacs L, Goth M, Szabolcs I et al. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 1998; 138: 543-547
15. Quin J, Gumpert J. Remission of non-insulin-dependent diabetes mellitus following resection of a parathyroid adenoma. Diabet Med 1997; 14: 80-81
16. Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol 2006; 155: 33-39
17. Gunal A, Celiker H, Celebi H, Ustundag B, Gunal S. Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin Nephrol 1997; 48: 109-113
18. Kautzky-Wilier A, Pacini G, Barnas U et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47: 200-206
19. Lu K, Shieh S, Lin S et al. Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure. Q J Med 1994; 87: 359-365
20. Fadda GZ, Akmal M, Lipson LG, Massry SG. Direct effect of parathyroid hormone on insulin secretion from pancreatic islets. Am J Physiol 1990; 258: 975-984
21. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul D, Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2006; 91: 4260-4263
22. Anastasilakis A, Goulis D, Koukoulis G et al. Acute and chronic effect of teriparatide on glucose metabolism in women with established osteoporosis. Exp Clin Endocrinol Diabetes 2007; 115: 108-111
23. Phillips D, Clark P, Hales C, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Med 1994; 11: 286-292
24. Wareham N, Phillips D, Byrne C, Hales C. The 30 minute insulin incremental tesponse in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 1995; 12: 931
25. Thomas DM, Rogers SD, Sleeman MW et al. Modulation of glucose transport by parathyroid hormone and insulin in UMR 106-01, a clonal rat osteogenic sarcoma cell line. J Mol Endocrinol 1995; 14: 263-275
26. Zablocki K, Michalik M, Bryla J. Substrate-dependent effect of 1-34 human parathyroid hormone fragment, dibutyryl cAMP and cAMP on gluconeogenesis in rabbit renal tubules. Biochim Biophys Acta 1986; 886: 483-490
27. Kumar S, Olukoga AO, Gordon C et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 40: 47-53
28. Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A. Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2001; 54: 805-811
29. Fliser D, Franek E, Fode P et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-938
30. Yamaguchi T, Sugimoto T. Calcium homeostasis and diabetes mellitus. Clin Calcium 2006; 16: 10-15
31. Nowicki M, Fliser D, Fode P, Ritz E. Changes in plasma phosphate levels influence insulin sensitivity undet euglycemic conditions. J Clin Endocrinol Metab 1996; 81: 156-159
32. Prager R, Schernthaner G, Kovarik J et al. Primary hyperparathyroidism is associated with decreased insulin receptor binding and glucose intolerance. Calcif Tissue Int 1984; 36: 253-258
33. Frager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonseder R. Peripheral insulin resistance in primary hyperparathyroidism. Metabolism 1983; 32: 800-805
34. MacCarty M, Thomas C. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 2003; 61: 535-542
35. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470